Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

被引：10
|
作者：
Jerkeman, Mats
Hutchings, Martin
Raty, Riikka
Wader, Karin Fahl
Laurell, Anna
Christensen, Jacob H.
Kuitunen, Hanne
Eskelund, Christian Winther
Groenbaek, Kirsten
Niemann, Carsten Utoft
Geisler, Christian H.
Kolstad, Arne
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    M Wang
    N Fowler
    N Wagner-Bartak
    L Feng
    J Romaguera
    S S Neelapu
    F Hagemeister
    M Fanale
    Y Oki
    B Pro
    J Shah
    S Thomas
    A Younes
    C Hosing
    L Zhang
    K J Newberry
    M Desai
    N Cheng
    M Badillo
    M Bejarano
    Y Chen
    K H Young
    R Champlin
    L Kwak
    L Fayad
    Leukemia, 2013, 27 : 1902 - 1909
  • [42] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    Wang, M.
    Fowler, N.
    Wagner-Bartak, N.
    Feng, L.
    Romaguera, J.
    Neelapu, S. S.
    Hagemeister, F.
    Fanale, M.
    Oki, Y.
    Pro, B.
    Shah, J.
    Thomas, S.
    Younes, A.
    Hosing, C.
    Zhang, L.
    Newberry, K. J.
    Desai, M.
    Cheng, N.
    Badillo, M.
    Bejarano, M.
    Chen, Y.
    Young, K. H.
    Champlin, R.
    Kwak, L.
    Fayad, L.
    LEUKEMIA, 2013, 27 (09) : 1902 - 1909
  • [43] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [45] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
    Lee, Hun Ju
    Romaguera, Jorge E.
    Feng, Lei
    Desai, Aakash P.
    Zhang, Liang
    Fanale, Michelle
    Samaniego, Felipe
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Medeiros, Jeffrey L.
    Hartig, Kimberly
    Nomie, Krystle
    Ahmed, Makhdum
    Badillo, Maria
    Ye, Haige
    Oki, Yasuhiro
    Lin, Pei
    Nastoupil, Loretta
    Westin, Jason
    Wang, Michael
    ONCOLOGIST, 2017, 22 (05): : 549 - 553
  • [46] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
  • [47] Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
    Wang, Michael L.
    Lee, Hun
    Chuang, Hubert
    Wagner-Bartak, Nicolaus
    Hagemeister, Frederick
    Westin, Jason
    Fayad, Luis
    Samaniego, Felipe
    Turturro, Francesco
    Oki, Yasuhiro
    Chen, Wendy
    Badillo, Maria
    Nomie, Krystle
    DeLa Rosa, Maria
    Zhao, Donglu
    Lam, Laura
    Addison, Alicia
    Zhang, Hui
    Young, Ken H.
    Li, Shaoying
    Santos, David
    Medeiros, L. Jeffrey
    Champlin, Richard
    Romaguera, Jorge
    Zhang, Leo
    LANCET ONCOLOGY, 2016, 17 (01): : 48 - 56
  • [48] Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) trial
    Jerkeman, M.
    Kolstad, A.
    Laurell, A.
    Raty, R.
    Gnonbaek, K.
    Geisler, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial
    Eve, H. E.
    Bullard, S. H.
    Rule, S. A. J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 42 - 43
  • [50] EFFICACY AND SAFETY OF CONVENTIONAL-DOSE LENALIDOMIDE FOLLOWED BY LOW-DOSE MAINTENANCE LENALIDOMIDE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL): RESULTS FROM A UK PHASE II STUDY
    Eve, H. E.
    Bullard, S. H.
    Rule, S. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 222 - 222
12345